A practical reference on c-Met receptor: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-06-14 and is reviewed periodically as new material appears.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV; not a natural hormone. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Naming conventions differ across vendors and papers. |
| CAS Registry Number | 1401708-83-6 | Listed in some chemical databases; verify against primary sources. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Solubility | Soluble in DMSO; limited in water | Organic stock solutions are common in laboratory settings. |
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
== Later developments == In 1987 Pedro Cuatrecasas and Meir Wilchek were awarded the Wolf Prize in Medicine for the invention and development of affinity chromatography and its applications to biomedical sciences.
=== Taxonomy and nomenclature === Fungaria are central to systematics research based on the comparative study of preserved specimens. Each newly described species must be documented by a designated specimen deposited in a recognized public collection. Type specimens are the only absolute link between a fungal species name and its taxonomic application, and fungaria provide an unmatched source of genetic data from taxonomically authoritative material. Because a type specimen anchors a name rather than representing the full range of a species, accurate identification and revisionary work also depend on examining broader sets of authenticated specimens spanning geography, hosts, and time. In phylogenetic-taxonomic work, sequences from type material are the preferred reference points; when original types are too old to yield reliable DNA, recently collected epitypes may be designated to provide sequence-backed name anchors. Taxonomy in the post-genomic era increasingly relies on sequencing type specimens to anchor species hypotheses, while examination of a broad array of preserved specimens from different growth stages and geographic areas helps define the range of variation within a species. Sampling multiple specimens of the same species can also reveal misidentified material, cryptic species, and species complexes when molecular clusters do not match morphological determinations.
== Contributions == Notable organizations to which Eli Lilly and Company has provided funding include the Northern Ontario School of Medicine, Population Health Research Institute (PHRI) at McMaster University, University of Toronto, University of Washington, National Press Foundation, American Society of Hematology, Endocrine Society, European Society of Cardiology, HOPE Worldwide, AdvaMed, Centre for Addiction and Mental Health (CAMH), Hospital for Sick Children (SickKids), Princess Margaret Cancer Centre, Scarborough Health Network, Sinai Health System, Sunnybrook Health Sciences Centre, Arthritis Australia, Diabetes Canada, and Juvenile Diabetes Research Foundation. Notable lobbying organizations to which the company has contributed include Foundation for the National Institutes of Health, Innovative Medicines Canada, International Federation of Pharmaceutical Manufacturers & Associations, National Health Council, and Pharmaceutical Research and Manufacturers of America.
Sources: en.wikipedia.org
Einstein hosts one of the three inaugural MSTPs launched by the National Institutes of Health (NIH) in 1964. This fully-funded dual doctoral MD/PhD program provide integrated graduate and clinical training for aspiring physician-scientists. The MSTP includes waived tuition, a stipend, subsidized housing, and a sesquiennial retreat to the Edith Macy Conference Center. The first year of the program integrates medical school preclerkship curriculum with graduate school coursework and lab rotations. In the second year, trainees complete preclinical medical courses, take USMLE Step 1, and choose a PhD advisor based on lab rotations. Years three to five focus on PhD research, publication, and optional clinical activities, followed by intensive clinical clerkships in years six and seven after dissertation defense. While working in the lab, students engage in both pathology case studies and clinics to maintain clinical skills.
=== Environmental and health concerns === Fluoroalkenes and fluorinated alkynes are reactive and many are toxic for example perfluoroisobutene. To produce polytetrafluoroethylene various fluorinated surfactants are used, in the process known as Emulsion polymerization, and the surfactant included in the polymer can bioaccumulate.
=== Early work === Thomson's prize-winning master's work, Treatise on the motion of vortex rings, shows his early interest in atomic structure. In it, Thomson mathematically described the motions of Lord Kelvin's vortex theory of the atom. Thomson published a number of papers addressing both mathematical and experimental issues of electromagnetism. He examined the electromagnetic theory of light of James Clerk Maxwell, introduced the concept of electromagnetic mass of a charged particle, and demonstrated that a moving charged body would apparently increase in mass. Much of his work in mathematical modelling of chemical processes can be thought of as early computational chemistry. In further work, published in book form as Applications of dynamics to physics and chemistry (1888), Thomson addressed the transformation of energy in mathematical and theoretical terms, suggesting that all energy might be kinetic. His next book, Notes on recent researches in electricity and magnetism (1893), built upon Maxwell's Treatise upon electricity and magnetism, and was sometimes referred to as "the third volume of Maxwell." In it, Thomson emphasized physical methods and experimentation and included extensive figures and diagrams of apparatus, including a number for the passage of electricity through gases. His third book, Elements of the mathematical theory of electricity and magnetism (1895) was a readable introduction to a wide variety of subjects, and achieved considerable popularity as a textbook.
Sources: en.wikipedia.org
2-Pentanol (IUPAC name: pentan-2-ol; also called sec-amyl alcohol) is an organic chemical compound. It is used as a solvent and an intermediate in the manufacturing of other chemicals. 2-Pentanol is a component of many mixtures of amyl alcohols sold industrially. 2-Pentanol is chiral and thus can be obtained as either of two stereoisomers designated as (R)-(−)-2-pentanol and (S)-(+)-2-pentanol. 2-Pentanol has been detected in fresh bananas by gas chromatography–mass spectrometry, at an abundance of 14.26±2.63 ppm.
If pregnancy occurs, LH levels will decrease, and luteal function will instead be maintained by the action of hCG (human chorionic gonadotropin), a hormone very similar to LH but secreted from the new placenta. Gonadal steroids (estrogens and androgens) generally have negative feedback effects on GnRH-1 release at the level of the hypothalamus and at the gonadotropes, reducing their sensitivity to GnRH. Positive feedback by estrogens also occurs in the gonadal axis of female mammals and is responsible for the midcycle surge of LH that stimulates ovulation. Although estrogens inhibit kisspeptin (Kp) release from kiss1 neurons in the ARC, estrogens stimulate Kp release from the Kp neurons in the anteroventral periventricular nucleus (AVPV). As estrogens' levels gradually increase the positive effect predominates, leading to the LH surge. GABA-secreting neurons that innervate GnRH-1 neurons also can stimulate GnRH-1 release. These GABA neurons also possess ERs and may be responsible for the GnRH-1 surge. Part of the inhibitory action of endorphins on GnRH-1 release is through inhibition of these GABA neurons. Rupture of the ovarian follicle at ovulation causes a drastic reduction in estrogen synthesis and a marked increase in secretion of progesterone by the corpus luteum in the ovary, reinstating a predominantly negative feedback on hypothalamic secretion of GnRH-1.
Inhaling heroin appears to rarely lead to toxic leukoencephalopathy. There are also documented cases of both severe acute asthma and exacerbation of underlying asthma caused by heroin inhalation, potentially resulting in death.
=== Indications === The α-bungarotoxin is among the most well-characterized snake toxins, with its high affinity and specificity for nicotinic acetylcholine receptors. It is a competitive antagonist at nAChR, where it irreversibly and competitively blocks the receptor at the acetylcholine binding sites. It binds to the α1 subunit contained in muscle nAChRs, as well as subsets of neuronal nAChRs like α7-α10. In addition, it was shown that α-bungarotoxin binds to, and block, a subset of GABAA receptors where the β3 subunits connect with each other. With this knowledge in mind, researchers can use α-bungarotoxin as an experimental tool for studying the properties of cholinergic receptors. In addition, by knowing the different and specific binding sites, researchers are able to visualize and track receptor localization and dynamics within cells. This technique has been shown to be easy with the use of a 13-amino acid (WRYYESSLEPYPD) mimotope, which forms a high affinity α-bungarotoxin binding site with the receptors. It has been extensively used in research to study the localization and distribution of these receptors. Through techniques like fluorophore or enzyme conjugation followed by microscopy or immunohistochemical staining, respectively, could give insights about the complex organization and function of the nervous system. With the mentioned techniques, researchers can work towardards a drug development, and understand the disease mechanism. They can idenitify potential drug targets by selectively regulating the activity of certain receptors.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.
No. Dihexa shares a conceptual link to angiotensin IV but has different structural features. Those changes are intended to modify its behavior in biological systems.
It often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. Synonyms and CAS listings vary, so cross-checking identifiers is necessary.
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.